Acne Inversa-Like Lesions Associated With The Multi-Kinase Inhibitor Sorafenib

Sorafenib, a multikinase inhibitor used for treating advanced renal clear-cell carcinoma and hepatocellular carcinoma, was associated with significant cutaneous toxicity due to its effects on skin and hair follicle pathways. Approximately 70-90% of patients experienced at least one skin-related side effect, with hand-foot skin reactions being the most common (48%), followed by subungual splinter hemorrhage (60%), alopecia (26-27%), stomatitis (26%), and other skin conditions. The appearance of these skin toxicities during treatment was suggested to indicate successful antitumor activity.